AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Sophia Frentzas, Tarek Meniawy, Steven Chuan-Hao Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, Wei Tan

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021

Cite this